Clinical Trial Update: Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy

View source ↗

Summary

Completed real-world study of locally advanced or metastatic non-small cell lung cancer patients who progressed after first-line EGFR-TKI therapy. The snippet d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic NSCLC | Status: COMPLETED